OR WAIT null SECS
January 10, 2025
Article
Submission of the supplemental NDA was based on positive findings from the FINEARTS-HF trial investigating finerenone for heart failure with an LVEF ≥40%.
4D-150 shows promising efficacy and safety in DME as FDA greenlights Phase 3 trial for Biologics License Application submission.
January 09, 2025
After accepting the avacincaptad pegol sNDA on January 6, 2025, the FDA has set a target action date for February 26.
January 08, 2025
The designation follows positive topline data from the phase 2a trial of CNP-104 in PBC, which were presented at AASLD’s The Liver Meeting
January 04, 2025
In this edition of HCPLive’s newsletter on monthly US Food and Drug Administration (FDA) news, we cover updates from across therapeutic pipelines in December.
December 31, 2024
To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.
December 30, 2024
The field of allergy medicine this year saw a variety of developments, including the FDA approvals of neffy and omalizumab as well as new data on immunotherapy.
December 29, 2024
This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.
December 26, 2024
The proposed rule seeks to establish and require standardized testing methods to detect and identify asbestos in cosmetic products with talc.
This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.
